N&PD Moderators: Skorpio
You should upgrade or use an alternative browser.I Like to Draw Pictures of Random Molecules
Incunabula
Bluelighter
![]()
I don't take stimulants or empathogens any more, so I don't really care. It was just a funny thought I had, and I thought I'd share it. I'd rather bet my money on this one being more worthwhile, than that mexedrone fail. (not that I've treid that one either, it's not my thing really)sekio
Bluelight Crew
Incunabula
Bluelighter
![]()
Incunabula
Bluelighter
Midnight Sun
Bluelighter
If you're trying to increase potency I think it's a better bet to mess around with constraining the basic tryptamine amide ala 4-ho-mpmi and/or indazole substitutions in lieu of indole
pretty sure the pocket of 5ht2a that LSD's diethylamide docks in is rather unreasonable to try and reach with an open chain (would be just too floppy)
I'd really like to know what the rationale was that led to the discovery of 4-HO-MPMI cause it sure would be enlightening!pharmakos
Bluelighter
add a ketone on that methyl bridge, and tack a pentyl group onto the indolic nitrogen, and you'd have a potential cannabinoid ![]()
aced126
Bluelighter
pretty sure the pocket of 5ht2a that LSD's diethylamide docks in is rather unreasonable to try and reach with an open chain (would be just too floppy)
I'd really like to know what the rationale was that led to the discovery of 4-HO-MPMI cause it sure would be enlightening!
I wasn't really trying to improve potency. In fact the reason why LSD is so potent itself is probably because it is in a rigidified conformation.
Idk, dimethyl > pyrrolidine is a pretty obvious modification lol; I'm sure they synthesised molecules with much more complex modifications.
I think conformal rigidity might be an issue. The alkyls on the amide appear to be required for space-filling since some secondary amides also work. It's that N lone-pair that is the important bit. The NBOMe class overlays the O of the benzyl-methyl ether so I would look at the directions of the lone-pairs. Just a thought - I could be miles out.
Without a fully constrained lysergamide structure nor such a phenyl substitution pattern on a non-constrained open chain compound you are apparently missing too many binding sites incl. on both ends, for the molecule to both fit on the receptor AND activate it by doing something to the conformation of the receptor protein. An uncanny likeness on one side of the molecule but not the other just makes the above structures remote meth / stim neurotransmitter cousins that apparently are generic enough to do the job as a sympathomimetic drug.sekio
Bluelight Crew
But it's been made though, refs
Horii et al. Chemical and Pharmaceutical Bulletin, 1966 , vol. 14, p. 1227-1234
Bulletin de la Societe Chimique de France, 1968 , p. 4463
Apparently it has oxytocic activity, so presumably it hits some of the serotonin receptors ?aced126
Bluelighter
But it's been made though, refs
Horii et al. Chemical and Pharmaceutical Bulletin, 1966 , vol. 14, p. 1227-1234
Bulletin de la Societe Chimique de France, 1968 , p. 4463
Apparently it has oxytocic activity, so presumably it hits some of the serotonin receptors ?
I meant to have the double bond there, but I couldn't manage to find a way to name it on Opsin. I have a feeling removal of the indole system will still retain activity to an extent.
Anyway, if the double bond is needed for activity, what does that say about how the molecule interacts with the pocket? Even a small conformational change results in a massive drop in potency, implying that the rigid structure which LSD takes is crucial to not only binding to, but also activating it. Yet however other 5HT2a agonists which have a similar backbone to LSD (like DMT for example) are very active of course, only at 2 or 3 orders of magnitude higher. With that being said, would dihydro-LSD and lumi-LSD be active when administered in much higher doses?
On to a different question, is there a structural link I am missing between the 2C-X series and tryptamine series as they both hit the same receptors.